15 New Medications Chosen for 2025 Medicare Price Negotiation
Each year, the Department of Health and Human Services (HHS) selects a list of prescription drugs that Medicare will work to lower prices for through negotiations. This year’s list includes 15 medications that are commonly used by older Americans to manage various health conditions. Amongst these drugs are Janumet for diabetes treatment, Otezla for psoriatic arthritis, Ozempic, Rybelsus, and Wegovy for diabetes, cardiovascular disease, and obesity, and Trelegy Ellipta for Chronic Obstructive Pulmonary Disease.
The widespread use of these medications highlights the importance of negotiating lower prices to make healthcare more affordable for patients and taxpayers alike. Richard Fiesta, the Executive Director of the Alliance, emphasized the significance of these negotiations in saving billions of dollars annually. It is crucial for the upcoming administration to prioritize patient needs and strive for fair deals in these negotiations.
Drug corporations have until February 28, 2025, to decide whether they will participate in the negotiations. This opportunity for negotiation presents a chance to make healthcare more accessible and affordable for those who rely on these medications for their well-being.
In conclusion, the selection of these 15 drugs for Medicare price negotiation marks a step towards making essential medications more affordable for the aging population in America. It is imperative for the government and drug companies to work together in these negotiations to prioritize patient well-being and reduce healthcare costs for all.
Leave feedback about this